ArticleSurgical case reports2026
Successful Conversion Surgery after Zolbetuximab-Based Chemotherapy for Claudin 18.2-Positive Gastric Cancer with Peritoneal Dissemination and Cervical Lymph Node Metastasis: A Case Report.
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Conversion surgery after response to zolbetuximab-based chemotherapy in Claudin 18.2-positive gastric cancer: a case report.Journal of surgical case reports · 2026Article
- Surgical Intervention After Zolbetuximab-Based Chemotherapy for CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A Case Series.Journal of gastrointestinal cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionZolbetuximab, a monoclonal antibody targeting claudin (CLDN) 18.2, has been approved as a first-line treatment for patients with human epidermal growth factor receptor 2 (HER2)-negative and CLDN-positive advanced gastric cancer. Conversion surgery following chemotherapy has emerged as a promising strategy for improving outcomes in patients with stage IV gastric cancer. Herein, we report a case of CLDN-positive gastric cancer with peritoneal dissemination and cervical lymph node metastasis that was successfully treated with subtotal gastrectomy (sTG) following zolbetuximab-based chemotherapy. CASE PRESENTATION: A 73-year-old male was diagnosed with HER2-negative, CLDN-positive gastric cancer, accompanied by peritoneal dissemination and cervical lymph node metastasis. He received 6 cycles of zolbetuximab in combination with capecitabine and oxaliplatin as first-line chemotherapy. Primary tumor, peritoneal lesions, and lymph node metastases exhibited marked regression, including complete resolution of the metastatic cervical lymph nodes. Complete response was achieved according to the Response Evaluation Criteria for Solid Tumors. After confirming the disappearance of the peritoneal dissemination, the patient underwent sTG with D2 lymphadenectomy. Histopathological examination revealed a grade 2 therapeutic response and no residual lymph node metastasis. The postoperative course was uneventful, and the patient remained recurrence-free for 5 months after the conversion surgery.
conclusionsZolbetuximab-based chemotherapy followed by conversion surgery is a promising therapeutic strategy for patients with CLDN-positive advanced gastric cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.